Skip to main content

Advertisement

SpringerLink
Log in

HMG-CoA Reductase Inhibitors for Traumatic Brain Injury

  • Review
  • Published:
Neurotherapeutics

Abstract

Traumatic brain injuries (TBIs) are associated with high morbidity and mortality due to both the original insult as well as the destructive biological response that follows. Medical management aims to slow or even halt secondary neurological injury while simultaneously laying the groundwork for recovery. Statins are one class of medications that is showing increased promise in the management of TBI. Used extensively in cardiovascular disease, these drugs were originally developed as competitive inhibitors within the cholesterol production pipeline. They are now used in diverse disease states due to their pleiotropic effects on other biological processes such as inflammation and angiogenesis. Preclinical studies, retrospective reviews, and randomized clinical trials have shown a variety of benefits in the management of TBI, but to date, no large-scale randomized clinical trial has been performed. Despite this limitation, statins’ early promise and well-tolerated side effect profile make them a promising new tool in the management of TBIs. More bench and clinical studies are needed to delineate proper treatment regimens as well as understand their true potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Maas AIR, et al. Traumatic brain injury: integrated approaches to improve prevention, clinical care, and research. Lancet Neurol. 2017;16:987–1048.

    Article  PubMed  Google Scholar 

  2. Frieden TR, Houry D, Baldwin G. Traumatic Brain injury in the United States: epidemiology and rehabilitation. CDC NIH Rep to Congr. 2015;1–74. 

  3. Feigin VL, et al. Incidence of traumatic brain injury in New Zealand: a population-based study. Lancet Neurol. 2013;12:53–64.

    Article  PubMed  Google Scholar 

  4. Rosenfeld Jv, et al. Early management of severe traumatic brain injury. Lancet. 2012;380:1088–1098.

  5. Plassman BL, et al. Documented head injury in early adulthood and risk of Alzheimer’s disease and other dementias. Neurology. 2000;55:1158–66.

    Article  CAS  PubMed  Google Scholar 

  6. Mahler B, et al. Unprovoked seizures after traumatic brain injury: a population-based case-control study. Epilepsia. 2015;56:1438–44.

    Article  PubMed  Google Scholar 

  7. Hart T, et al. Major and minor depression after traumatic brain injury. Arch Phys Med Rehabil. 2011;92:1211–9.

    Article  PubMed  Google Scholar 

  8. Riggio S, Wong M. Neurobehavioral sequelae of traumatic brain injury. Mount Sinai Journal of Medicine: J Transl Pers Med. 2009;76:163–72.

    Article  Google Scholar 

  9. Rohling ML, Faust ME, Beverly B, Demakis G. Effectiveness of cognitive rehabilitation following acquired brain injury: a meta-analytic re-examination of Cicerone et al.’s (2000, 2005) systematic reviews. Neuropsychology. 2009;23:20–39.

  10. Bullock MR, et al. Surgical management of traumatic brain injury. Neurosurgery. 2006;58:16–24.

    Google Scholar 

  11. Timofeev I, et al. Ventriculostomy for control of raised ICP in acute traumatic brain injury. 2008;99–104. https://doi.org/10.1007/978-3-211-85578-2_20.

  12. Chang BS, Lowenstein DH. Practice parameter: antiepileptic drug prophylaxis in severe traumatic brain injury. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2003;60:10–16.

  13. Rangel-Castillo L, Gopinath S, Robertson CS. Management of intracranial hypertension. Neurol Clin. 2008;26:521.

    Article  PubMed Central  Google Scholar 

  14. Marehbian J, Muehlschlegel S, Edlow BL, Hinson HE, Hwang DY. Medical management of the severe traumatic brain injury patient. Neurocritical Care. 2017;27(3):430–446.

  15. Gruenbaum SE, Zlotnik A, Gruenbaum BF, Hersey D, Bilotta F. Pharmacologic neuroprotection for functional outcomes after traumatic brain injury: a systematic review of the clinical literature. CNS Drugs. 2016;30:791–806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Temkin NR, et al. Magnesium sulfate for neuroprotection after traumatic brain injury: a randomised controlled trial. Lancet Neurol. 2007;6:29–38.

    Article  CAS  PubMed  Google Scholar 

  17. Lulic D, Burns J, Bae EC, van Loveren H, Borlongan Cv. A review of laboratory and clinical data supporting the safety and efficacy of cyclosporin A in traumatic brain injury. Neurosurgery. 2011;68:1172–1186.

  18. Farooqui AA, Ong WY, Horrocks LA, Chen P, Farooqui T. Comparison of biochemical effects of statins and fish oil in brain: the battle of the titans. Brain Res Rev. 2007;56:443–71.

    Article  CAS  PubMed  Google Scholar 

  19. Steinberg, D. Thematic review series: the pathogenesis of atherosclerosis. An interpretive history of the cholesterol controversy, part V: The discovery of the statins and the end of the controversy. J Lipid Res. 2006;47:1339–1351.

  20. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res. 1992;33:1569–82.

    Article  CAS  PubMed  Google Scholar 

  21. Pedersen TR, et al. Effect of simvastatin on ischemic signs and symptoms in the scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333–5.

    Article  CAS  PubMed  Google Scholar 

  22. Lin SY, et al. Trends in use and expenditures for brand-name statins after introduction of generic statins in the US, 2002–2018. JAMA Netw Open. 2021;4:e2135371–e2135371.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature. 1990;343:425–30.

    Article  CAS  PubMed  Google Scholar 

  24. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discover 2005;4(12):977–987.

  25. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 2000;6.

  26. Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation. 1999;100:230–5.

  27. Pannu R, Barbosa E, Singh AK, Singh I. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res. 2005;79:340–50.

    Article  CAS  PubMed  Google Scholar 

  28. Ehrenstein MR, Jury EC, Mauri C. Statins for atherosclerosis — as good as it gets? N Engl J Med. 2005;352:73–5.

    Article  CAS  PubMed  Google Scholar 

  29. Katznelson S, et al. The effect of pravastatin on acute rejection after kidney transplantation–a pilot study. Transplantation. 1996;61:1469–74.

    Article  CAS  PubMed  Google Scholar 

  30. Anderson TJ, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488–93.

    Article  CAS  PubMed  Google Scholar 

  31. Balakumar P, Kathuria S, Taneja G, Kalra S, Mahadevan N. Is targeting eNOS a key mechanistic insight of cardiovascular defensive potentials of statins? J Mol Cell Cardiol. 2012;52:83–92.

    Article  CAS  PubMed  Google Scholar 

  32. Mauch DH, et al. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 2001;294:1354–7.

    Article  CAS  PubMed  Google Scholar 

  33. Fan Q-W, et al. Cholesterol-dependent modulation of dendrite outgrowth and microtubule stability in cultured neurons. J Neurochem. 2002;80:178–90.

    Article  CAS  PubMed  Google Scholar 

  34. Zacco A, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci. 2003;23:11104–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Johnson-Anuna LN, et al. Simvastatin protects neurons from cytotoxicity by up-regulating Bcl-2 mRNA and protein. J Neurochem. 2007;101:77–86.

    Article  CAS  PubMed  Google Scholar 

  36. Wu H, Mahmood A, Qu C, Xiong Y, Chopp M. Simvastatin attenuates axonal injury after experimental traumatic brain injury and promotes neurite outgrowth of primary cortical neurons. Brain Res. 2012;1486:121–30.

    Article  CAS  PubMed  Google Scholar 

  37. McFarland AJ, et al. Molecular mechanisms underlying the effects of statins in the central nervous system. Int J Mol Sci. 2014;15:20607–20637 15, 20607–20637.

  38. Garcia M, Reinoso R, Sanchez Navarro A, Prous J. Clinical pharmacokinetics of statin. Methods Find Exp Clin Pharmacol. 2003;25:457–481.

  39. Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol. 1991;14:256–61.

    Article  CAS  PubMed  Google Scholar 

  40. Johnson-Anuna LN, et al. Chronic administration of statins alters multiple gene expression patterns in mouse cerebral cortex. J Pharmacol Exp Ther. 2005;312:786–93.

    Article  CAS  PubMed  Google Scholar 

  41. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA. 2003;289:1681–90.

    Article  CAS  PubMed  Google Scholar 

  42. Ganga Hv, Slim HB, Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Am Heart J. 2014;168:6–15.

  43. Russo MW, et al. Spectrum of statin hepatotoxicity: experience of the drug-induced liver injury network. Hepatology. 2014;60:679–86.

    Article  CAS  PubMed  Google Scholar 

  44. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618–24.

    Article  CAS  PubMed  Google Scholar 

  45. Swerdlow DI, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Riaz H, et al. Meta-analysis of placebo-controlled randomized controlled trials on the prevalence of statin intolerance. Am J Cardiol. 2017;120:774–81.

    Article  CAS  PubMed  Google Scholar 

  47. Mountney A, et al. Simvastatin treatment in traumatic brain injury: operation brain trauma therapy. J Neurotrauma. 2016;33:567–80.

    Article  PubMed  Google Scholar 

  48. Chen S-F, et al. Lovastatin improves histological and functional outcomes and reduces inflammation after experimental traumatic brain injury. Life Sci. 2007;81:288–98.

    Article  CAS  PubMed  Google Scholar 

  49. Wang H, et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206:59–69.

    Article  CAS  PubMed  Google Scholar 

  50. Wu H, et al. Induction of angiogenesis and modulation of vascular endothelial growth factor receptor-2 by simvastatin after traumatic brain injury. Neurosurgery. 2011;68:1363–71.

    Article  PubMed  Google Scholar 

  51. Wang K-W, et al. Simvastatin combined with antioxidant attenuates the cerebral vascular endothelial inflammatory response in a rat traumatic brain injury. Biomed Res Int. 2014;2014:1–6.

    Article  Google Scholar 

  52. Xu X, et al. Anti-inflammatory and immunomodulatory mechanisms of atorvastatin in a murine model of traumatic brain injury. J Neuroinflammation. 2017;14:167.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Lu D, et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg. 2004;101:813–21.

    Article  CAS  PubMed  Google Scholar 

  54. Lu D, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma. 2004;21:21–32.

    Article  PubMed  Google Scholar 

  55. Lu D, et al. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J Neurotrauma. 2007;24:1132–46.

    Article  PubMed  Google Scholar 

  56. Darwish H, Mahmood A, Schallert T, Chopp M, Therrien B. Simvastatin and environmental enrichment effect on recognition and temporal order memory after mild-to-moderate traumatic brain injury. Brain Inj. 2014;28:211–26.

    Article  PubMed  Google Scholar 

  57. Xie C, et al. The effect of simvastatin treatment on proliferation and differentiation of neural stem cells after traumatic brain injury. Brain Res. 2015;1602:1–8.

    Article  CAS  PubMed  Google Scholar 

  58. Mahmood A, et al. Long-term benefits after treatment of traumatic brain injury with simvastatin in rats. Neurosurgery 2009;65:187–91, discussion 191–2.

  59. Mountney A, et al. Intravenous administration of simvastatin improves cognitive outcome following severe traumatic brain injury in rats. J Neurotrauma. 2016;33:1492–500.

    Article  PubMed  Google Scholar 

  60. Lu D, et al. Delayed thrombosis after traumatic brain injury in rats. J Neurotrauma. 2004;21:1756–66.

    Article  PubMed  Google Scholar 

  61. Lu D, et al. Atorvastatin reduction of intracranial hematoma volume in rats subjected to controlled cortical impact. J Neurosurg. 2004;101:822–5.

    Article  PubMed  Google Scholar 

  62. Abrahamson EE, et al. Cerebral blood flow changes after brain injury in human amyloid-beta knock-in mice. J Cereb Blood Flow Metab. 2013;33:826–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Khokhar B, et al. Mortality and associated morbidities following traumatic brain injury in older medicare statin users. Journal of Head Trauma Rehabilitation. 2018;33:E68–76.

    Article  PubMed  Google Scholar 

  64. Mansi IA, English JL, Alvarez CA, Mortensen EM, Pugh MJ. Statins in survivors of traumatic brain injury: a propensity score-matched analysis. Brain Inj. 2020;34:1367–74.

    Article  PubMed  Google Scholar 

  65. Redelmeier DA, Manzoor F, Thiruchelvam D. Association between statin use and risk of dementia after a concussion. JAMA Neurol. 2019;76:887.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Li M, et al. Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer’s disease after traumatic brain injury. Alzheimers Res Ther. 2020;12:33.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Sánchez-Aguilar M, et al. Effect of rosuvastatin on cytokines after traumatic head injury. J Neurosurg. 2013;118:669–75.

    Article  PubMed  Google Scholar 

  68. Tapia-Perez JH, et al. Effect of rosuvastatin on amnesia and disorientation after traumatic brain injury (NCT003229758). J Neurotrauma. 2008;25:1011–7.

    Article  PubMed  Google Scholar 

  69. Naghibi T, Madani S, Mazloomzadeh S, Dobakhti F. Simvastatin’s effects on survival and outcome in traumatic braininjury patients: a comparative study. Turk J Med Sci. 2016;46:1–5.

    Article  CAS  PubMed  Google Scholar 

  70. Soltani F, et al. The effect of low-dose atorvastatin on inflammatory factors in patients with traumatic brain injury: a randomized clinical trial. Arch Neurosci. 2020;7.

  71. Shafiee S, et al. The effect of oral simvastatin on the clinical outcome of patients with severe traumatic brain injury: a randomized clinical trial. Ethiop J Health Sci. 2021;31:807–16.

    PubMed  PubMed Central  Google Scholar 

  72. Lokhandwala A, et al. Preinjury statins are associated with improved survival in patients with traumatic brain injury. J Surg Res. 2020;245:367–72.

    Article  CAS  PubMed  Google Scholar 

  73. Farzanegan GR, Derakhshan N, Khalili H, Ghaffarpasand F, Paydar S. Effects of atorvastatin on brain contusion volume and functional outcome of patients with moderate and severe traumatic brain injury; a randomized double-blind placebo-controlled clinical trial. J Clin Neurosci. 2017;44:143–7.

    Article  CAS  PubMed  Google Scholar 

  74. Schneider EB, et al. Premorbid statin use is associated with improved survival and functional outcomes in older head-injured individuals. J Trauma. 2011;71:815–9.

    CAS  PubMed  Google Scholar 

  75. Neilson SJ, See AAQ, King NKK. Effect of prior statin use on outcome after severe traumatic brain injury in a South-East Asian population. Brain Inj. 2016;30:993–8.

    Article  PubMed  Google Scholar 

  76. Orlando A, et al. Unintentional discontinuation of statins may increase mortality after traumatic brain injury in elderly patients: a preliminary observation. J Clin Med Res. 2013;5:168–73.

    CAS  PubMed  PubMed Central  Google Scholar 

  77. Robertson CS, et al. Phase II clinical trial of atorvastatin in mild traumatic brain injury. J Neurotrauma. 2017;34:1394–401.

    Article  Google Scholar 

  78. Govindarajan KA, et al. Cortical Thickness in mild traumatic brain injury. J Neurotrauma. 2016;33:1809–17.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, Baylor College of Medicine, Houston, TX, 77030, USA

    Kalman Katlowitz, Shankar Gopinath, Jovany Cruz Navarro & Claudia Robertson

Authors
  1. Kalman Katlowitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shankar Gopinath
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jovany Cruz Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Claudia Robertson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kalman Katlowitz.

Ethics declarations

Conflict of Interest

None.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Katlowitz, K., Gopinath, S., Cruz Navarro, J. et al. HMG-CoA Reductase Inhibitors for Traumatic Brain Injury. Neurotherapeutics 20, 1538–1545 (2023). https://doi.org/10.1007/s13311-023-01399-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13311-023-01399-9

Keywords

Search

Navigation